Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PTN

Palatin Technologies Inc

Feb 06 • 04:00PM ET

15.72

-0.33 -2.06 %

Healthcare • Biotechnology • USA • AMEX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-13.19	Insider Own	9.51%	Shs Outstand	1.70M	Perf Week	6.87%
Market Cap	26.77M	Forward P/E	-	EPS next Y	-1.87	Insider Trans	-0.35%	Shs Float	1.54M	Perf Month	-9.97%
Enterprise Value	25.63M	PEG	-	EPS next Q	-2.35	Inst Own	26.73%	Short Float	13.38%	Perf Quarter	141.85%
Income	-4.81M	P/S	3.02	EPS this Y	86.17%	Inst Trans	32.29%	Short Ratio	3.21	Perf Half Y	42.91%
Sales	8.85M	P/B	38.61	EPS next Y	57.95%	ROA	-79.90%	Short Interest	0.21M	Perf YTD	2.21%
Book/sh	0.41	P/C	21.08	EPS next 5Y	55.89%	ROE	-	52W High	69.00 -77.22%	Perf Year	-63.70%
Cash/sh	0.75	P/FCF	-	EPS past 3/5Y	44.66% 23.09%	ROIC	-1212.46%	52W Low	1.75 798.29%	Perf 3Y	-92.28%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-4.96%	Volatility	11.34% 13.11%	Perf 5Y	-98.62%
Dividend TTM	-	EV/Sales	2.90	EPS Y/Y TTM	87.20%	Oper. Margin	-116.21%	ATR (14)	2.13	Perf 10Y	-97.38%
Dividend Ex-Date	-	Quick Ratio	1.02	Sales Y/Y TTM	271.10%	Profit Margin	-54.32%	RSI (14)	46.41	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.02	EPS Q/Q	121.60%	SMA20	-3.73%	Beta	0.45	Target Price	54.33
Payout	-	Debt/Eq	0.33	Sales Q/Q	-	SMA50	-14.29%	Rel Volume	0.15	Prev Close	16.05
Employees	29	LT Debt/Eq	0.00	Earnings	Nov 13 BMO	SMA200	46.30%	Avg Volume	64.25K	Price	15.72
IPO	Oct 28, 1993	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	9,481	Change	-2.06%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-25	Initiated	Laidlaw	Buy	$60
Dec-03-25	Initiated	Alliance Global Partners	Buy	$50

Nov-13-25 07:30AM	Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (PR Newswire)
Nov-12-25 12:15PM	Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option (PR Newswire) +29.43%

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WILLS STEPHEN T	Executive VP and CFO/COO	Dec 24 '25	Sale	16.74	565	9,461	63,488	Dec 29 04:30 PM
WILLS STEPHEN T	Director	Dec 24 '25	Proposed Sale	16.74	565	9,461		Dec 29 10:42 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTN

Palatin Technologies Inc

Upgrade your FINVIZ experience